Corrigendum: JCS/JHRS 2022 Guideline on Diagnosis and Risk Assessment of Arrhythmia (Circulation Journal (2024) 88 (1509-1595) DOI: 10.1253/circj.CJ-22-0827)

There were errors in the text regarding the wording and timing of approval, and the statement that these devices are not in the category of controlled medical devices. Corrections are shown below. Page 1517, “3.6.6 Smartphones, Smartwatches” section Incorrect: Specifications of “Home heart rate monitoring programs” for smartphones and “Home ECG programs” for smartwatches were approved in January 2021 in Japan as “Home medical devices” that detect and suggest disease symptoms and encourage the individual to seek medical attention, rather than as categories such as general medical devices or controlled medical devices. Correct: Specifications of “Home heart rate monitoring programs” for smartphones and “Home ECG programs” for smartwatches were approved in January 2021 in Japan as “controlled medical devices” that detect and suggest disease symptoms and encourage individuals to seek medical attention. The first version of the package inserts was created in August 2020, and commercialization started alongside domestic approval in January 2021. The package inserts were revised as second editions in May 2023 and November 2022, respectively.